CeriBell Reports 30% Revenue Growth in Q3 2026 Driven by Record Account Usage
CeriBell (CBLL) reported strong third-quarter 2026 financial results, with total revenue rising 30% year-over-year to $29.3 million. This growth was fueled by a 31% increase in product revenue and a 28% rise in subscription revenue, supported by record usage per account and the addition of 35 net new hospital customers. The company also achieved an improved gross margin of 90%, aided by manufacturing efficiencies in Vietnam. Despite the top-line strength, CeriBell reported a widening net loss of $21.4 million due to increased commercial investments and R&D for its upcoming Omni platform. Management is pivoting from pure seizure detection toward establishing EEG as a standard vital sign through new AI algorithms and delirium monitoring solutions. The company maintains a strong liquidity position with $117.5 million in cash and marketable securities to support its path toward cash flow breakeven.
Tickers: $CBLL
Topics: gross margin guidance net loss revenue growth subscription revenue